Siro Perez

Siro leads the Life Sciences team of investment company IP Group plc (LSE:IPO) in Australia, investing in spin-out companies out of the top universities in Australia and New Zealand.

He has over nineteen years of scientific and international management experience across the whole research, development, commercialisation, and investment process in new technologies.

Prior to joining IP Group, he was the Co-Founder and CEO of University of Queensland’s spin out company Molecular Warehouse, a medical diagnostics platform. He was also a Venture Partner at Hadean Ventures, a life sciences venture capital fund, and founder of Roundcape, a boutique advisory firm advising and co-founding startups.

Previously, he served as CEO of ToxiMet, leading the company from a development stage start-up to a fully commercial enterprise (acquired by Bio-Check UK). Before joining ToxiMet, he worked investing in pharmaceutical and biotech stocks for one of the world’s leading hedge funds ($14B under management), and as Investment Manager for Nestle’s Corporate Venture Fund ($1.5B under management).

Prior to his CEO and investment career, he worked as Project Leader in the Zurich office of The Boston Consulting Group, managing strategy projects for global Pharma and Biotech companies. Before that, he led a group in drug development and conducted research in neurodegenerative diseases at Novartis in Basel, Switzerland, and started his scientific career at the Cajal Institute of Neurobiology in Madrid, Spain. He has multiple publications in international peer-reviewed journals.

Siro hold a Masters in Finance from the London Business School, and a PhD summa cum laude in Molecular Biology and a MSc in Chemistry with honours from the Autonoma University of Madrid. He also studied Computer Science Engineering at UNED, and speak English, German, and Spanish fluently.